share_log

Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12

Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12

Benchmark以投機性買入評級啓動對Intensity Therapeutics的報道,宣佈目標股價爲12美元
Benzinga ·  2023/07/18 06:56

Benchmark analyst Robert Wasserman initiates coverage on Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy rating and announces Price Target of $12.

基準分析師羅伯特·瓦瑟曼開始對Intensity Therapeutics(納斯達克股票代碼:INTS)進行投機性買入評級,並宣佈目標股價爲12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論